Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
نویسندگان
چکیده
Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris–Seine Saint-Denis, Site Jean Verdier, Pôle d’Activité Cancérologique Spécialisée, Service d’Hépatologie, Bondy, France; INSERM, Unité Mixte de Recherche (UMR) 1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue contre le Cancer, Paris, France; Université Paris Descartes, Labex Immuno-Oncology, Sorbonne Paris Cité, Paris, France; Université Paris 13, Sorbonne Paris Cité, Unité de Formation et de Recherche (UFR), Santé, Médecine, Biologie Humaine (SMBH), Bobigny, France; Université Paris Diderot, Institut Universitaire d’Hématologie, Paris, France; Division of Gastroenterology and Hepatology, Fondazione IRCCS C. a Granda Ospedale Maggiore Policlinico di Milano, Universita degli Studi di Milano, Milan, Italy
منابع مشابه
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates r...
متن کاملالگوهای جدید درمانی برای عفونت ویروس هپاتیت C
Hepatitis C virus (HCV) infection has affected approximately 180 million people across the world. In most cases, HCV-infection remains chronic, which expose patients at high risk of cirrhosis and hepatocellular carcinoma. The rates of disease incidence and mortality diminish as a result of successful treatment of HCV infection. Until the recent years, despite the associated toxicities and l...
متن کاملDirect-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
BACKGROUND AND AIMS Arrival of direct-acting antiviral agents against hepatitis C virus with high-sustained virological response rates and very few side effects has drastically changed the management of hepatitis C virus infection. The impact of direct-acting antiviral exposure on hepatocellular carcinoma recurrence after a first remission in patients with advanced fibrosis remains to be clarif...
متن کاملStatin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents [version 3; referees: 2 approved]
Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs). However, despite successful viral clearance, many patients continue to have HCV-related disease progression. Therefore, new treatments must be developed to achieve viral clearance and prevent the risk of HCV-related diseases. In particular, the...
متن کاملStatin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents [version 2; referees: 2 approved]
Recent improvements have been made in the treatment of hepatitis C virus (HCV) infection with the introduction of direct-acting antiviral agents (DAAs). However, despite successful viral clearance, many patients continue to have HCV-related disease progression. Therefore, new treatments must be developed to achieve viral clearance and prevent the risk of HCV-related diseases. In particular, the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of hepatology
دوره 65 4 شماره
صفحات -
تاریخ انتشار 2016